Study tracks early adoption of liver histotripsy treatment
It has been nearly three years since the U.S. Food and Drug Administration (FDA) cleared the HistoSonics Edison histotripsy system to treat primary and metastatic liver tumors. To examine how the technology's adoption and use have progressed, a research team at the University of Virginia, led by All
<p>It has been nearly three years since the U.S. Food and Drug Administration (FDA) cleared the HistoSonics Edison histotripsy system to treat primary and metastatic liver tumors. To examine how the technology's adoption and use have progressed, a research team at the University of Virginia, led by All</p>